

- 1.) "Familial Hypercholesterolemia Model of Care" (2008). Office of Population Health Genomics, Government of Western Australia. Accessed online at http://www.genomics.health.wa.gov.au/fh/docs/FH_Model_of_care.pdf on May 10, 2011.
- 2.) McGowan M (2010). "Screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions." *J. Clin. Lipidology* 4 (5) 335-337.
- 4.) Defesche J (2010). "Defining the challenges of FH Screening for familial hypercholesterolemia" *J. Clin. Lipidology* 4 (5) 338-341.
- 5.) Hopkins P (2010). "Defining the challenges of familial hypercholesterolemia screening: Introduction." *J. Clin. Lipidology* 4 (5) 342-345.
- 6.) Hemphill L (2010). "Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis." *J. Clin. Lipidology* 4 (5) 346-349.
- 7.) Goldberg A (2010). "Novel therapies and new targets of treatment for familial hypercholesterolemia." *J. Clin. Lipidology* 4 (5) 350-356.
- 8.) McGowan M (2010). "FH Symposium Question-and-answer session." *J. Clin. Lipidology* 4 (5) 357-358.
- 9.) Daniels SR, Greer FR; Committee on Nutrition (2008). "Lipid screening and cardiovascular health in childhood." *Pediatrics*. 2008 Jul;122(1):198-208.
- 10.) McCrindle BW, Urbina EM, Dennison BA, et al (2007). "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing." *Circulation*. 2007;115:1948-1967.
- 11.) Gidding S (2006). "New Cholesterol Guidelines for Children?" *Circulation*. 2006;114:989-991.
- 12.) Gidding S (2010). "Assembling Evidence to Justify Prevention of Atherosclerosis Beginning in Youth." *Circulation*. 2010;122:2493-2494.
- 13.) Gidding S (2010). "Familial Hypercholesterolemia: A Decade of Progress." Department of Pediatrics Faculty Papers. Paper 21. Accessed online at <http://jdc.jefferson.edu/pedsfp/21> on May 10, 2011.
- 14.) Steinberg D, Glass CK, Witztum JL (2008). "Evidence mandating earlier and more aggressive treatment of hypercholesterolemia." *Circulation*. 2008 Aug 5;118(6):672-7.
- 15.) De Ferranti S, Ludwig DS (2008). "Storm over statins: the controversy surrounding pharmacologic treatment of children." *N Engl J Med*. 2008 Sep 25;359(13):1309-12.

- 16.) Ito MK (2007). "ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?" *Ann Pharmacother*. 2007 Oct;41(10):1669-78.
- 17.) Kavey RE, Allada V, Daniels SR, et al (2006). "Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research." *Circulation*. 2006 Dec 12;114(24):2710-38.
- 18.) Rader DJ, Cohen J, Hobbs HH (2003). "Monogenic hypercholesterolemia: new insights in pathogenesis and treatment." *J. Clin. Invest*. 111 (12): 1795–803.
- 19.) Greene O, Durrington P (2004). "Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK." *J R Soc Med* 97 (5): 226–9.
- 21.) Ritchie SK, Murphy EC, Ice C, et al (2010). "Universal versus targeted blood cholesterol screening among youth: The CARDIAC project." *Pediatrics*. 126(2):260–265.
- 22.) Thorsson B, Sigurdsson G, Gudnason V (2003). "Systematic family screening for familial hypercholesterolemia in Iceland." *Arterioscler Thromb Vasc Biol*. 23(2):335-8.
- 23.) Campagna F, Martino F, Bifulco M, et al (2008). "Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: Results of a family and DNA-based screening." *Atherosclerosis*. 2008;196:356–364.
- 24.) Civeira F (2004). "Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia." *Atherosclerosis*. 173(1):55-68.
- 25.) Hobbs HH, Russell DW, Brown MS, et al (1990). "The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein." *Annu Rev Genet*. 1990;24:133-70.
- 26.) Williams RR, Hunt SC, Schumacher MC, et al (1993). "Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah." *Am J Cardiol*. 72(2):171-6.
- 27.) Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J (1995). "Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation." *Circulation* 1995;92:290-295.
- 28.) Sijbrands EJ, Westendorp RG, Defesche JC, et al (2001). "Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study." *BMJ* 322 (7293): 1019–23.

- 29.) Ford ES, Li C, Zhao C, Mokdad A. "Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States." *Circulation* 2009;119:1108-1115.
- 30.) Williams RR, Hasstedt SJ, Wilson DE, (1986). "Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees." *JAMA*. 1986 Jan 10;255(2):219-24.
- 33.) Marks D, Wonderling D, Thorogood M, et al (2002). "Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia." *BMJ* 324 (7349): 1303.
- 34.) Civeira F, Ros E, Jarauta E, et al (2008). "Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia." *Am J Cardiol*. 102(9):1187-93.
- 35.) Wald DS, Bestwick JP, Wald NJ (2007). "Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis." *BMJ*. 2007 Sep 22;335(7620):599.
- 36.) Watts G, van Bockxmeer F, Bates T, et al. "A New Model of Care for Familial Hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology." *Heart, Lung & Circulation*. 2010.
- 37.) "Risk of fatal coronary heart disease in familial hypercholesterolaemia." (1991). Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ*. 1991 Oct 12;303(6807):893-6.
- 38.) Neil A, Cooper J, Betteridge J, et al (2008). "Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study." *Eur Heart J* 2008;29:2625-2633.
- 39.) Amsellem S, Briffaut D, Carrié A, et al (2002). "Intronic mutations outside of Alu-repeat-rich domains of the LDL receptor gene are a cause of familial hypercholesterolemia." *Hum Genet*. 2002 Dec;111(6):501-10.
- 40.) Leren TP (2004). "Cascade genetic screening for familial hypercholesterolemia." *Clin Genet*. 2004 Dec;66(6):483-7.
- 41.) Williams RR, Hunt SC, Schumacher MC, et al. "Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics." *Am J Cardiol*. Jul 15 1993;72(2):171-6.
- 42.) DeMott K, Nherera L, Shaw EJ, et al (2008). "Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia." 2008. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.

- 43.) Taylor A, Wang D, Patel K, et al (2010). "Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project." *Clin Genet*. 2010 Jun;77(6):572-80.
- 44.) Tosi I, Toledo-Leiva P, Neuwirth C, et al (2007). "Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic."
- 45.) Civeira F, Jarauta E, Cenaarro A, et al (2008). "Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting." *J Am Coll Cardiol*. 52(19):1546-53.
- 46.) Starr B, Hadfield SG, Hutten BA, et al (2008). "Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing." *Clin Chem Lab Med*. 2008;46(6):791-803.
- 47.) Damgaard D, Larsen ML, Nissen PH, et al (2005). "The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population." *Atherosclerosis*. 180(1):155-60.
- 48.) Costanzo, Perrone-Filardi P, Vassallo E, et al (2010). "Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials." *J Am Coll Cardiol*. 2010;56:2006-20.
- 49.) Finn AV, Kolodgie FD, Virmani R (2010). "Correlation Between Carotid Intimal/Medial Thickness and Atherosclerosis: A Point of View From Pathology." *Arterioscler Thromb Vasc Biol*. 2010;30:177-181.
- 50.) Oosterveer DIM, Versmissen J, Yazdanpanah M, et al (2010). "The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway." *European Heart Journal* 2010;31:1007-1012.
- 51.) Oosterveer DM, Versmissen J, Yazdanpanah M, et al (2009). "Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: A systematic review and meta-analysis." *Atherosclerosis* 2009;207:311-317.
- 52.) Vergeer M, Zhou R, Bots ML, et al (2010). "Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients: A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE Studies." *Circ Cardiovasc Imaging* 2010;3:398-404.
- 54.) Alonso R, Mata N, Castillo S, et al (2008). "Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors." *Atherosclerosis* 2008;200:315-321.

- 55.) Humphries SE, Whittall RA, Hubbart CS, et al (2006). "Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk." *Journal of Medical Genetics* 2006;43:943-949.
- 56.) Neil HAW, Seagroatt V, Betteridge DJ, et al (2004). "Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia." *Heart* 2004;90:1431-1437.
- 57.) Bertolini S, Cantafora A, Averna M, et al (2000). "Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype." *Arterioscler Thromb Vasc Biol* 2000;20:e41-52.
- 58.) Wiesbauer F, Blessberger H, Azar D, et al (2009). "Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<=40 years of age)." *Eur Heart J* 2009;30:1073-1079.
- 59.) Hill J, Hayden M, Frohlich J, Pritchard P (1991). "Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia." *Arterioscler Thromb* 1991;11:290-297.
- 61.) Junyent M, Gilabert R, Jarauta E, et al (2009). "Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia." *Atherosclerosis* 2009;208:437-441.
- 62.) Wierzbicki AS, Humphries SE, Minhas R, on behalf of the Guideline Development Group (2008). "Familial hypercholesterolaemia: summary of NICE guidance." *BMJ* 2008;337:a1095-.
- 63.) Jansen ACM, van Aalst-Cohen ES, Tanck MW, et al (2004). "The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients." *Journal of Internal Medicine* 2004;256:482-490.
- 64.) Humphries SE, Whittall RA, Hubbart CS, et al (2006). "Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk." *Journal of Medical Genetics* 2006;43:943-949.
- 65.) Minhas R, Humphries SE, Qureshi N, Neil HA, on behalf of the NGDG (2009). "Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia." *Heart* 2009;95:584-587.